Richard Gelber
机构: Professor, Harvard Medical School, Harvard TH Chan School of Public Health, Dana-Farber Cancer Institute, Frontier Science Foundation
每年引用次数
引用次数
引用: 123,984
H-指数: 154
I10-指数 : 496
出版物: 861
Special Sabbatical for Training in Health Decision Sciences with Application to Breast Cancer Treatment Evaluation.
Richard D. Gelber
1996
Patterns of treatment effects in subsets of patients in clinical trials
Richard D. Gelber , Marco Bonetti
Biostatistics 5 ( 3) 465 -481
126
2004
Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer
David W. Hedley , Catherine A. Rugg , Richard D. Gelber
Cancer Research 47 ( 17) 4729 -4735
239
1987
Effect o f P regnancy o n O verall S urvival A fter t he Diagnosis o f E arly-Stage B reast C ancer
Anne Gudgeon , Jurij Lindtner , David Z. Edelmann , Alan S. Coates
293
2001
Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial
Astrid Kiermaier , Evandro de Azambuja , Debora Fumagalli , Jose Bines
Cancer Research 81
2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Alvaro Moreno-Aspitia , Eileen M Holmes , Christian Jackisch , Evandro de Azambuja
European Journal of Cancer 148 287 -296
2021
Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Matteo Lambertini , Samuel Martel , Christine Campbell , Sebastien Guillaume
Journal of Clinical Oncology 36 10065 -10065
2018
Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.
Evandro De Azambuja , Noam Falbel Ponde , Marion Jennifer Procter , Priya Rastogi
Journal of Clinical Oncology 36 10066 -10066
2
2018
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
Gunter Von Minckwitz , Marion Jennifer Procter , Evandro De Azambuja , Dimitrios Zardavas
Journal of Clinical Oncology 35
9
2017
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Matteo Lambertini , Samuel Martel , Christine Campbell , Sébastien Guillaume
Cancer 125 ( 2) 307 -316
30
2019
Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Jose P Leone , Bernard F Cole , Meredith M Regan , Beat Thürlimann
Cancer 127 ( 5) 700 -708
2021
Outcome of Dana-Farber Cancer Institute (DFCI) Consortium Protocol 95–01 for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).
Lewis B. Silverman , Donna E. Levy , Virginia K. Dalton , Steven E. Lipshultz
Blood 104 ( 11) 679 -679
2
2004
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
Alan S. Coates , Aparna Keshaviah , Beat Thürlimann , Henning Mouridsen
Journal of Clinical Oncology 25 ( 5) 486 -492
778
2007
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter , Marion Procter , Dirk J. van Veldhuisen , Michael Muscholl
Journal of Clinical Oncology 25 ( 25) 3859 -3865
447
2007
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
Clifford A. Hudis , William E. Barlow , Joseph P. Costantino , Robert J. Gray
Journal of Clinical Oncology 25 ( 15) 2127 -2132
530
2007
The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer
Per Karlsson , Bernard F. Cole , Karen N. Price , Alan S. Coates
Journal of Clinical Oncology 25 ( 15) 2019 -2026
63
2007
Are We RESPECTing Older Patients With Breast Cancer
Evandro de Azambuja , Noam Pondé , Richard D Gelber ,
Journal of Clinical Oncology 38 ( 32) 3727 -3730
2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
Martine J. Piccart , Florentine S. Hilbers , Judith M. Bliss , Carmela Caballero
Journal of Clinical Oncology 38 ( 34) 4120 -4129
22
2020
A Method-of-Moments Estimation Procedure for Categorical Quality-of-Life Data with Nonignorable Missingness
Marco Bonetti , Bernard F. Cole , Richard D. Gelber
Journal of the American Statistical Association 94 ( 448) 1025 -1034
11
1999
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
Marco Colleoni , Bernard F. Cole , Giuseppe Viale , Meredith M. Regan
Journal of Clinical Oncology 28 ( 18) 2966 -2973
161
2010